IDEAYA Biosciences, Inc.
NASDAQ:IDYABiotechnology
-$0.45 today
- Market cap
- $2.53B
- Beta
- -0.05
- P/E (TTM)
- -19.5
- EPS (TTM)
- -$1.58
Volume 1.42M
Average 1.44M
Returns on capital
IDEAYA Biosciences, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-11.1%
avg -0.2%
ROIC
-15.2%
avg -32.2%
ROA
-10.2%
avg -25.8%
Analysis
ROA is currently the strongest return metric at -10.2% versus its period average of -25.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Yujiro S. Hata | Founder, President, CEO & Chairman | USD 1.09M | 52 | 23.12K | 0.02% |
Darrin Beaupre | Chief Medical Officer | USD 738.3K | 59 | 175.00K | 0.18% |
Michael A. White | President of Research & Development | USD 728.3K | 61 | — | — |
Joshua Bleharski | Chief Financial Officer | USD 683.35K | 51 | 170.00K | 0.18% |
Douglas Snyder | Chief Legal Officer | USD 668.52K | 62 | — | — |
Andres Ruiz Briseno | Chief Accounting Officer | USD 600.8K | 40 | 19.20K | 0.02% |
Stuart Dorman | Chief Commercial Officer | USD 161.82K | 48 | 155.00K | 0.16% |
Jasgit Sachdev | Senior Vice President of Late Phase Clinical Development & Strategy | — | — | — | — |
Paul A. Barsanti | Chief Technology Officer | — | — | — | — |
Daniel A. Simon | Chief Business Officer | — | — | — | — |
Mick O'Quigley | Senior Vice President of Medical Writing & Project Management | — | — | — | — |
Francine Zelaya | Senior VP & Head of Human Resources | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 6, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$1.65M
Sells
3
$1.37M
Net Transaction Value
+$280,362.43
Net buying
Most Active
Hata Yujiro S
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 6, 26Oct 6, 2026 | Hata Yujiro S Direct | Sell | $30.6K$30,610.08 |
| Oct 6, 26Oct 6, 2026 | Hata Yujiro S Direct | Sell | $954.8K$954,786.65 |
| Jul 7, 26Jul 7, 2026 | Ruiz Briseno Andres Direct | Sell | $382.1K$382,130.84 |
| Mar 2, 26Mar 2, 2026 | Stein Jeffrey Direct | Buy | $1.6M$1,647,890.00 |
Summary
Insiders reported 1 buys worth $1.65M and 3 sells worth $1.37M over the last 12 months. That adds up to net buying of $280,362.43. Hata Yujiro S was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +62.5% | +31.8% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +62.5% over three years. Forward estimates point to Revenue at +31.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does IDEAYA Biosciences, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about IDYA's management, answered from reported figures.
Who manages IDYA?
IDEAYA Biosciences, Inc. (IDYA) lists 12 active executives. The top listed executive is Jasgit Sachdev, Senior Vice President of Late Phase Clinical Development & Strategy.
Are IDYA insiders buying or selling?
Recent insider activity shows net buying of $136.29M.
Continue the stock analysis
Jump to another research area for this company.